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Introduction: Biomarkers of Toxicity During
Pregnancy
by Richard K. Miller*
Pregnancy brings a series of physiological and bio-
chemical changes that transform awoman from a single
functioning unit to an organism within an organism.
During pregnancy, there are two sets of genomes in-
terfacing through a unique organ called the placenta.
Dynamic change is observed throughout pregnancy for
the female of all mammalian species. When superim-
posed upon pregnancy, the exposure to a therapeutic
orenvironmental agent produces multiple factors. Does
the agent affect only the mother, only the conceptus,
only the placenta, or all three? These unique interac-
tions are based upon alterations during pregnancy and
the appearance oftwo functioning units. Unique phys-
iological and biochemical characteristics of pregnancy
include the presence of two separate blood supplies;
rapid and selective growth of specific cell types in the
conceptus at particular stages ofconception; and direct
and indirect interactions among the mother, embryo/
fetus, and placenta (1). Function of maternal organs,
not to mention the embryonic/fetal organs, may be sub-
stantially different at specific stages ofgestation. Thus,
the challenge to the clinician and scientist is to assess
pregnancy/developmental status and the impact ofsuch
xenobiotic exposure upon the conceptus.
To assess such impact, biomarkers have been used
for generations. Clinical signs of amenorrhea, nausea,
weightgain, the appearance ofan embryonicheartbeat,
and fetal movement have all been used for centuries.
Such biomarkers have substantial limitations in sensi-
tivity or the early documentation of pregnancy, e.g.,
fetalmovement orquickeningbeinggreaterat 16weeks
ofgestation, or nonspecificity, e.g., amenorrhea, an in-
fertility problem and not pregnancy. Certainly the de-
velopment of specific hormone assays, such as mea-
surement of human chorionic gonadotropin (hCG), has
provided a greater specificity to detect pregnancy (2).
The evolution of this hCG assay from a bioassay to a
highly sensitive enzyme immunoassay has provided
boththepatient andthe clinicianthecapabilitytodetect
a pregnancy before the clinical signs ofa pregnancy are
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noted, i.e., the absent menstrual period. Such a bio-
marker has been atremendous asset to the care ofboth
the pregnant patient and the infertile couple. A new
terminology has developed surrounding such a bio-
marker and its early assessment: chemical pregnancy.
In past years, many women would experience a late
menstrual period and attribute it to an altered cycle;
however, today, because ofthe sensitivity ofthese as-
says that enable early detection of pregnancy, many
more pregnancies are being documented that fail early.
The introduction ofsuch a sensitive biomarker initially
suggested that women today were being exposed to
toxins that produced early pregnancy loss because of
the tremendous increase in documented early preg-
nancy loss. However, what was actually observed was
the efficiency ofnormal humanreproduction, which had
not been previously documented. Such documentation
of early pregnancy loss in a population demonstrates
how critical it is to use a biomarker appropriately for
the assessment of normal function and for the assess-
ment ofpotentially toxic influences on that function.
Thus, in relationship to pregnancy, many ofthe nor-
mal biomarkers of maternal function and development
cannot be easily extrapolated to toxicity assessment.
Obviously, the premier goal of the following papers is
to assess the state-of-the-art for all biomarkers related
to reproduction and development and to assess these
biomarkers in relationship to selected adverse effects
on either mother or conceptus for specific exposure.
Biomarkers related to pregnancy and development
can be divided into two major categories: exposure or
toxicokinetics, and effects or toxicodynamics (Table 1).
Obviously, the objective for performing any of these
assessments is to determine whether a therapeutic or
environmental exposure has produced a detectable in-
sult to mother or conceptus. The second objective is to
determine if this insult can be detected or estimated
sufficiently early to prevent or reverse the observed
insult. For example, the detection of the birth defect
spina bifida (open neural tube) is easily documented at
birth. However, it is important to know that this defect
is present before parturition so that the method of de-
livery may be altered. Ultrasonography has been mostR. K. MILLER
Maternal
Serum/plasma
Urine
Feces
Hair
Nails
Tissue biopsy
Endometrium
Cervical mucus
Follicular fluid
Uterine washings
Fat
Products of conception
Placental: Products ofconception
Chorionic villus biopsy (early)
Amnion
Chorion
Umbilical cord
Fetal blood/serum/plasma
Amniotic fluid
Embryo/fetus: Products ofconception
Tissue analysis
Blood/serum/plasma
Hair
Nails
Urine
Feces
Amniocentesis
Amniotic fluids
Fetal cells
Foreskin
Maternal: Steroids
Uterine prolactin
Immune responses
HLA
TLX
Histology
Vaginal epithelium
Endometrium
Cervical mucus
Toxic screens
Binding globulins and other proteins
Uterine blood flow changes
Pregnancy-associated carcinogenesis
(Trophoblastic neoplasia)
Placental: Hormones
Human chorionic gonadotropin
Human placental lactogen
cACTH
cFSG
cTSH
PAPP-A
Interferon
Interleukin I
Estradiol
Estriol
Progesterone
Receptors
,B-adrenergic
Glucocorticoid
Table 1. Biomarkers associated with pregnancy.
Epidermal growth factor
Folate
Immunoglobulin (IgG-Fc)
Low density lipoproteins
Opiates
Somatomedin
Testosterone
Transcobalamin II
Transferrin
TCDD
Binders and other proteins/tissue products
Transcobalamin I/II/III
a-Fetoprotein
Enzymes and carrier proteins
DNA adducts
Nutrient and xenobiotic metabolism
Nutient and xenobiotic transport
Karyotyping
Morphometry
Histology
Embryo and fetus:
Tissue-specific antigens
CEA
a-Fetoprotein
Immunoglobulins
Physical examinations
Physical
Carcinogenesis
Dysmorphology
Apgar/Braselton
Death
Incidence ofpregnancy loss
Growth retardation
Growth Factors
IGF
EGF
NGF
Physiology
Inborn errors ofmetabolism
Organ system specific
Cardiovascular
Hepatic
Renal
Neural
Others
Assessment tools (current)
Amniocentesis
Chorionic villus biopsy
Doppler blood flow
Fetal blood sampling
Fetal heart rate monitoring
Fetoscopy
Magnetic resonance imaging
Products ofconception
Ultrasound real time
Intact organ chemiluminescence
Incidence ofpregnancy loss
Fluid and tissue analysis
Molecular genetic/DNA probes
In vitro comparisons
helpful in documenting the appearance of spina bifida
in utero. However, there are limitations to ultrasono-
graphyindetectingthedefectduringthefirsttrimester.
The introduction of maternal serum and amniotic fluid
a-fetoproteins as indicators of neural tube defects has
beenmosthelpfulintheearlydetectionofsuchadefect.
Yet, the goal ofthis type ofinvestigation is the devel-
opment of a biomarker which establishes that the pa-
tient/conceptus is atriskforhavingsuch adefectbefore
the defectis apparent. Ifriskdetection ispossible, then
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modificationofexposureandpossiblecorrectivetherapy
for the exposed patient orconceptus maybe possible to
eliminate such a problem.
Such goals of reduced exposure or identification of
susceptible individuals, whether mother or conceptus,
require new directions for identifying biomarkers, but
even more importantly, these goals require an ex-
tremelyjudiciousvalidationprocessfordeterminingthe
usefulness ofeach biomarker. To assess these goals for
perinatal toxicology and the potential for achieving
them, internationally recognized experts in the field of
reproduction and toxicology have been asked to discuss
biomarkers of both effect and exposure, applying the
latestintechnologicaladvancesandcriteriaofvalidation
to the issues of human risk analysis.
In addition to the assessment of hCG, perhaps the
premier biochemical marker for assessing the risk of
birth defects in the human is the measurement of a-
fetoprotein (AFP). At the NAS Symposium, David Er-
ickson, from the Center for Disease Control in Atlanta,
Georgia, reviewed the usefulness of AFP in maternal
serum and amniotic fluid as a biomarker ofrisk. It was
stressed that both the sensitivity and specificity of a
test are essential to its predictive value, where sensi-
tivityistheprobabilitythatAFPwillindicatetheneural
tube defect given the actual presence ofthe disease. A
perfectbiomarker interms ofsensitivity would notgive
false negatives. Specificity refers to the ability ofAFP
to indicate the absence of neural tube defects when
there is no disease present. Thus, the use of a bio-
marker, e.g., maternal serum AFP, has limited use-
fulness as the only tool for identifying neural tube de-
fects because of the sensitivity levels; however,
maternal serum AFP is a successful screen in combi-
nation with other clinical tools (e.g., ultrasonography,
chromosomal screening, or acetylcholinesterase activ-
ity), and it has potential usefulness as a screen for as-
sociations between valproate therapy or insulin-depen-
dent diabetes mellitus and neural tube defects. These
biomarkers are the types required for screening pro-
grams which reduce misidentification of an individual
who is at risk for a neural tube defect from a large and
heterogeneous population.
Amongthemostexcitingareasofinvestigationtoday,
two relate to the early, shared signals between the en-
dometrium and trophoblast that reflect the capability
of the embryo to implant and develop. Many of these
issues have been further enhanced by the international
success oftheinvitrofertilization programs. Thus, once
fertilization has occurred, the major issues are related
to how the implantation process may be affected and
limited by either maternal orfetal factors. Such factors
may be the tissue development, the specific signals pro-
duced, or the specific antigens carried on the tropho-
blast, in addition to the obvious chromosomal issues of
perimplantation lethality. Stanley Glasser has assessed
these signals from both the trophoblast and endome-
trium as potential biomarkers for pregnancy outcome
and toxic influence (3). W. Page Faulk has documented
the importance of cell-surface antigens on the tropho-
blast to the capability of the conceptus to survive im-
plantation (4). The importance of HLA antigens is re-
viewed as is the most exciting work on a TLX antigen
that has been associated with patients who are primary
spontaneousaborters. Suchbiomarkersfordetermining
the causes of failed pregnancy are essential to our un-
derstanding of how new biomarkers may be used to
eliminate nontherapeutic/environmental causesoffailed
pregnancies.
As gestation progresses, many other interventions
for assessing development have been used to evaluate
the impact ofxenobiotics not only on the fetus but also
on the mother. The assessment of fetal blood flow via
Doppler analysis and cardiac function via echocardiog-
raphy have beenreviewed by Lawrence Longo (5). The
ability to assess the effects ofhypoxia itself, as well as
the effects ofxenobiotic exposure, is beingidentified as
essential areas ofinvestigations for all perinatologists.
Obviously, thealterationsoffetalchestwallmovements
due to a single cocktail or to a cigarette illustrate the
capability of identifying effects on the fetus. Of equal
importance is establishing the importance of such
changes to the immediate function ofthe fetus and the
long-term development ofthe child.
Many assessments noted only identify the conse-
quences ofthe therapeutic or environmental exposure.
Often the only intervention is delivery, if that is pos-
sible. As stated above, the major objective of the use
ofbiomarkers is to identify susceptible populations and
eitherprevent ormodifythe outcome in apositive man-
ner. Thus, innovative work reviewed by Richard Ev-
erson implicated both the presence of an agent and its
ability to interact with cellular constituents in the con-
ceptus (6). In particular, studies have used placentae
from women who have smoked or were exposed to spe-
cificpolycyclic aromatichydrocarbons. Inthese tissues,
specific adducts to cellular DNA have been identified.
Currently, the patterns of DNA adducts formed from
many ofthese compounds appearto have ablot pattern
that is specific for the compound. Thus, the ability to
detect specific compounds reacting with fetal tissue
couldperhapsbeinitiallyassessedbysamplingchorionic
villus tissue. Such studies raise further interest in the
ability of other fetal tissues, e.g., amniotic fluid cells,
to produce a similar DNA-adduct proffle.
With the formation a specifically identifiable finger-
print DNA adduct for a compound, it may be possible
to assess not only affect but also exposure, which is the
second class of biomarkers. Perhaps the premier ex-
ample of estimating a dose-response relationship for a
human teratogen has uniquely occurred because ofthe
exposureofaruralpopulationoffamiliesinIraqtograin
treated with the fungicide methylmercury. Thomas
Clarkson and his team have intensively evaluated this
population for the past 15 years (7). Clarkson reports
methods whereby one can assessthe actualexposure to
methylmercury prior to, throughout, and well into the
postnatal period by assessing the content ofmercury in
a single strand ofhair. This ability to assess actual ex-
posurehasbeeninvaluable. Suchassessments havepro-
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vided the opportunity to determine the actual timing
and amount ofexposure inutero and postnatally. Dose-
response relationships have been documented. Thus, it
is possible that for selected metals, analysis ofhair and
correlation with other tissues and body fluids may be
essential to establishing risk even before conception.
To establish potential risk, estimating exposure to
methylmercury can be critical. To establish such ex-
posuretoothercompounds byusingabiomarkerisoften
extremely difficult. Pharmacokinetic assessments are
often measurements of only maternal blood or urine,
and extrapolations are performed to project levels in
the conceptus ormeasures oftissue content based upon
placental tissue or hair/fat analyses at delivery (8). Un-
fortunately, the inaccessibility ofthe conceptus haspre-
sented problems for such exposure monitoring during
pregnancy. However, Richard K. Miller reviews some
of the most recent advances in perinatology utilizing
magnetic resonance imaging (MRI) as a tool for eval-
uating the conceptus. In addition, in vitro models for
assessing the placental passage of therapeutic and en-
vironmental agents during a 24-hr period are evaluated
to establish the mechanism by which the human fetus
can be exposed to nutrients, drugs, and environmental
chemicals (8,9). The use ofmagnetic resonance imaging
to identify physical defects is but one possibility. To
assess individual organ function at a biochemical level
is the exciting potential for such spectroscopy. For ex-
ample, it has been possible under selective conditions
to measure phosphorus as ATP, ADP, AMP, and phos-
phocreatine. Such capabilities for the conceptus may
identify specific organresponse without awaiting agen-
eralized response ofthe conceptus. Toactually measure
the distribution of specific compounds is now possible.
However, limited studies have been performed in the
pregnantwomantodatebecause ofalackofinformation
concerning the effects of MRI itself on the pregnant
woman and the conceptus. Thus, for toxicokinetic pur-
poses, dual perfusion of the isolated human placental
cotelydon has provided the opportunity to assess ex-
tremely toxic agents, TCDD or cadmium, in the human
placenta without risk to either mother or conceptus.
Thus, the following chapters represent many state-
of-the-art applications which should stimulate the read-
er's imagination to explore further the issues ofthe use
of biomarkers of toxicity during pregnancy, whether
expressed as effect or exposure markers.
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